Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Market Cap
$62.8M
Volume
2.6M
Cash and Equivalents
$128.6M
EBITDA
-$140.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$6.5M
Profit Margin
N/A
52 Week High
$42.20
52 Week Low
$1.17
Dividend
N/A
Price / Book Value
0.43
Price / Earnings
-0.89
Price / Tangible Book Value
0.43
Enterprise Value
-$65.8M
Enterprise Value / EBITDA
0.47
Operating Income
-$141.4M
Return on Equity
17.19%
Return on Assets
-57.18
Cash and Short Term Investments
$128.6M
Debt
N/A
Equity
$145.7M
Revenue
N/A
Unlevered FCF
-$73.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium